Fadi Nasrallah, MD
Retina Specialist · Bethesda, MDNPI 1427055144
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Cardinal Health 108 LLC at 53.7% of the total. Reporting peaked in 2019 at $2,605 and has fallen 85.9% since, to $367 in 2025.
Across 40 payments — averaging $99.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardinal Health 108 LLC$2K
- AbbVie$223
- Alcon$216
- Novartis$191
- Kala Pharmaceuticals, Inc.$149
- Biotissue Holdings Inc.$148
- plus $907 from 9 others
What the payments were for
- Consulting fees$1,68843%
- Travel & lodging$44111%
- Food & beverage$1,83546%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardinal Health 108 LLC | 7 | $2,128 |
| AbbVie(2 entities) | 6 | $223 |
| Alcon | 5 | $216 |
| Novartis | 5 | $191 |
| Kala Pharmaceuticals, Inc. | 2 | $149 |
| Biotissue Holdings Inc. | 1 | $148 |
| Apellis Pharmaceuticals, Inc. | 2 | $147 |
| Bausch & Lomb Americas Inc. | 2 | $143 |
| Tarsus Pharmaceuticals, Inc. | 1 | $136 |
| Astellas Pharma US Inc | 2 | $128 |
| Sun Pharmaceutical Industries Inc. | 1 | $116 |
| Oyster Point Pharma, Inc. | 1 | $95 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $65 |
| Genentech USA, Inc. | 2 | $40 |
| Coherus Oncology, Inc. | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$148
- AmnioGraft$148
- XDEMVY$136
- INVELTYS$125
- IC-8 Apthera IOL$123
- enVista MX60 IOL$123
- LUMIGAN$117
- CEQUA$116
- TRYPTYR$115
- Syfovre$113
- Izervay$100
How this compares
$3,963 in reported general payments places this provider in the 65th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 11 | $20,842 |
| Brimonidine Tartrate | 15 | $1,944 |
| Bromfenac Sodium | 13 | $1,443 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Bethesda
- Grant JustinBethesda$4K
- Jordan HeffezBethesda$3K
- David ParverBethesda$2K
- Robert StephensBethesda$334
- Kevin BroderickBethesda$318
- Leonard ParverBethesda$19
- Rohit LakhanpalOwings Mills$168K
- Brian DoChevy Chase$116K
- Adam GerstenblithHagerstown$107K
- Aziz KhanifarSilver Spring$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.